As secretory IgA plays a crucial role in protecting mucosal surfaces against respiratory viruses and other pathogens, vaccine approaches via nebulization or intranasal delivery may enhance IgA levels in the upper airways and provide long-term protection against COVID-19. This evidence concerns the gene CD79A and COVID-19.